OTCPK:ANNI.F

Stock Analysis Report

Executive Summary

Annidis Corporation engages in the research, development, and sale of medical devices for eye-care professionals in the United States, China, and Canada.

Snowflake

Fundamentals

Mediocre balance sheet and slightly overvalued.

Risks

  • Annidis's last earnings update was 473 days ago.
  • Annidis is not covered by any analysts.

Share Price & News

How has Annidis's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

ANNI.F

1.2%

US Medical Equipment

-0.6%

US Market


1 Year Return

-99.0%

ANNI.F

9.7%

US Medical Equipment

0.7%

US Market

ANNI.F underperformed the Medical Equipment industry which returned 14.4% over the past year.

ANNI.F underperformed the Market in United States of America which returned -2.3% over the past year.


Share holder returns

ANNI.FIndustryMarket
7 Day0%1.2%-0.6%
30 Day0%3.5%4.9%
90 Day0%3.2%1.7%
1 Year-99.0%-99.0%10.6%9.7%3.0%0.7%
3 Yearn/a70.6%65.4%44.8%35.4%
5 Yearn/a139.4%112.2%62.0%44.3%

Price Volatility Vs. Market

How volatile is Annidis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Annidis undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Annidis's share price is below the future cash flow value, and at a moderate discount (> 20%).

Annidis's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Annidis is loss making, we can't compare its value to the US Medical Equipment industry average.

Annidis is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Annidis, we can't assess if its growth is good value.


Price Based on Value of Assets

Annidis has negative assets, we can't compare the value of its assets to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Annidis expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Annidis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of ANNI.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Annidis's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Annidis performed over the past 5 years?

33.5%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Annidis does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Annidis's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Annidis's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Annidis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Annidis has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Annidis improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is Annidis's financial position?


Financial Position Analysis

Annidis's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Annidis's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Annidis has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Annidis's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

Annidis has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Whilst loss making Annidis has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.

Whilst loss making Annidis has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -45.2% per year.


Next Steps

Dividend

What is Annidis's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Annidis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Annidis's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Annidis has not reported any payouts.

Unable to verify if Annidis's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Annidis has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Annidis's salary, the management and board of directors tenure and is there insider trading?

5.4yrs

Average board tenure


CEO

Gerald Slemko (66yo)

2.1yrs

Tenure

0

Mr. Gerald Slemko serves as President of Cuddy Farms, Inc. Mr. Slemko has been Interim Chief Executive Officer of Annidis Corporation since February 23, 2017. Mr. Slemko served as the Chief Executive Offic ...


CEO Compensation Analysis

Gerald's remuneration is lower than average for companies of similar size in United States of America.

Insufficient data for Gerald to compare compensation growth.


Board Age and Tenure

5.4yrs

Average Tenure

The tenure for the Annidis board of directors is about average.


Insider Trading

No 3 month insider trading information.


Management Team

  • Gerald Slemko (66yo)

    Executive Chairman & Interim Chief Executive Officer

    • Tenure: 2.1yrs
  • Mike McDonnell

    VP of Operations and Director Quality & Regulatory

    • Tenure: 0yrs
  • Brian Leonard

    Chairman of Medical Scientific & Advisory Board and Chief Medical Officer

    • Tenure: 0yrs
  • Dave Kahn

    Chief Technology Officer

    • Tenure: 0yrs

Board Members

  • Gerald Slemko (66yo)

    Executive Chairman & Interim Chief Executive Officer

    • Tenure: 2.1yrs
  • Zhi Gu Ying (69yo)

    Director

    • Tenure: 5.4yrs
  • Stuart Richer

    Medical Scientific and Advisory Board Member

    • Tenure: 0yrs
  • Brian Leonard

    Chairman of Medical Scientific & Advisory Board and Chief Medical Officer

    • Tenure: 0yrs
  • Jerome Sherman

    Medical Scientific and Advisory Board Member

    • Tenure: 0yrs
  • Stuart Coupland

    Medical Scientific and Advisory Board Member

    • Tenure: 0yrs
  • Bruce Jackson

    Medical Scientific and Advisory Board Member

    • Tenure: 0yrs
  • Stephen Sinclair

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Jason Zhang

    Director

    • Tenure: 5.4yrs
  • Tony Yu

    Director

    • Tenure: 5.4yrs

Company Information

Annidis Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Annidis Corporation
  • Ticker: ANNI.F
  • Exchange: OTCPK
  • Founded: 2007
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$1.099m
  • Listing Market Cap: CA$818.946k
  • Shares outstanding: 109.95m
  • Website: https://null

Location

  • Annidis Corporation
  • 100 Maple Grove Road
  • Ottawa
  • Ontario
  • K2V 1B8
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RHA.HTSXV (TSX Venture Exchange)YesCommon SharesCACADJun 2011
ANNI.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJun 2011

Biography

Annidis Corporation engages in the research, development, and sale of medical devices for eye-care professionals in the United States, China, and Canada. It offers RHA instrument, a multi-spectral imaging  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/03/11 00:51
End of Day Share Price2018/12/11 00:00
Earnings2017/09/30
Annual Earnings2016/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.